8-K: BioMarin Reports Strong Q3 Growth, Raises Full-Year Guidance

BioMarin Pharmaceutical Inc. announced a 28% year-over-year increase in total revenue for the third quarter of 2024 and raised its full-year guidance.

Summary

• BioMarin's total revenue for the third quarter of 2024 reached $746 million, a 28% increase compared to the same period in 2023, or 32% at constant currency.
• Year-to-date total revenue for 2024 is $2.11 billion, up 19% year-over-year, or 23% at constant currency.
• VOXZOGO revenue grew by 54% year-over-year in the third quarter, driven by strong demand.
• The Enzyme Therapies portfolio saw a 27% year-over-year revenue increase in the third quarter.
• GAAP diluted earnings per share (EPS) for the third quarter was $0.55, a 162% increase year-over-year, and year-to-date EPS is $1.56, up 103% year-over-year.
• Non-GAAP diluted EPS for the third quarter was $0.91, a 98% increase year-over-year, and year-to-date EPS is $2.60, up 63% year-over-year.
• The company generated $221 million in operating cash flow in the third quarter, a 63% increase compared to the same period last year.
• BioMarin settled $495 million of convertible debt in cash during the quarter, retiring approximately four million potentially dilutive shares.
• The company increased its full-year 2024 guidance for total revenue, non-GAAP operating margin, and non-GAAP diluted EPS.
• BioMarin reaffirmed its long-term guidance, targeting approximately $4 billion in total revenue in 2027 and a 40% non-GAAP operating margin starting in 2026.

Sentiment

Score: 9

Explanation: The document conveys a very positive sentiment due to strong financial results, increased guidance, and progress in clinical programs. The company's strategic initiatives and operational efficiency are also highlighted, contributing to the high sentiment score.

Positives

• BioMarin experienced strong revenue growth in the third quarter of 2024, driven by VOXZOGO and the Enzyme Therapies portfolio.
• The company's profitability increased significantly, with both GAAP and non-GAAP EPS showing substantial year-over-year growth.
• BioMarin generated strong operating cash flow and successfully retired convertible debt, reducing potential share dilution.
• The company is making progress in its clinical programs, including advancing studies for VOXZOGO in multiple indications and initiating studies for other pipeline candidates.
• BioMarin's updated full-year guidance reflects confidence in continued growth and profitability.
• The company is executing on its new corporate strategy focused on Innovation, Growth, and Value Commitment.

Negatives

• KUVAN product revenues decreased due to generic competition following the loss of market exclusivity in 2022.
• Increased spending in Selling, General and Administrative (SG&A) was partially due to severance and restructuring costs.
• ROCTAVIAN inventory reserves impacted the Cost of Sales.
• The company experienced higher income tax expenses.

Risks

• The company faces risks related to the commercialization of its products and the impact of macroeconomic factors.
• Clinical trial results and regulatory approvals are subject to uncertainty.
• Manufacturing and supply chain issues could impact the company's ability to meet product demand.
• The company is exposed to competition from generic products, particularly for KUVAN.
• The company's future performance depends on the successful execution of its corporate strategy and clinical development programs.

Future Outlook

BioMarin has increased its full-year 2024 guidance for total revenue, non-GAAP operating margin, and non-GAAP diluted EPS. The company also reaffirmed its long-term guidance, targeting approximately $4 billion in total revenue in 2027 and a 40% non-GAAP operating margin starting in 2026. They also expect to generate more than $1.25 billion operating cash flow per year starting in 2027 and a mid-teen compound annual growth rate (CAGR) for total revenues through 2034.

Management Comments

• Alexander Hardy, President and Chief Executive Officer of BioMarin, stated that the strategic and operational decisions made over the last nine months are driving strong performance.
• Mr. Hardy noted that the company is executing on its new corporate strategy focused on Innovation, Growth, and Value Commitment.
• Mr. Hardy highlighted the strong global demand for VOXZOGO, with over 3,800 infants and children receiving treatment as of the end of the third quarter.
• Mr. Hardy also noted the impressive results from the Enzyme Therapies portfolio, with a 27% year-over-year revenue growth in the third quarter.

Industry Context

BioMarin's strong performance in the third quarter reflects the growing demand for treatments for rare genetic conditions. The company's focus on innovation and expansion of its product portfolio aligns with industry trends in the biotechnology sector. The success of VOXZOGO and the Enzyme Therapies portfolio demonstrates the potential for targeted therapies in addressing unmet medical needs.

Comparison to Industry Standards

• BioMarin's 28% year-over-year revenue growth in Q3 2024 is strong compared to the average growth rate of many established biotech companies, which often see single-digit or low double-digit growth.
• The 54% year-over-year growth of VOXZOGO is particularly impressive, indicating a strong market uptake and potential for continued expansion. This is significantly higher than the growth rates of many other orphan drug products.
• The 27% growth in the Enzyme Therapies portfolio is also notable, suggesting that BioMarin is effectively managing and expanding its existing product lines. This is a good result compared to companies that rely on a single product.
• BioMarin's GAAP EPS growth of 162% and non-GAAP EPS growth of 98% in Q3 2024 are exceptional, indicating strong profitability improvements. Many biotech companies struggle to achieve such high growth rates in profitability.
• The company's operating cash flow of $221 million in Q3 2024, a 63% increase year-over-year, is a positive sign of financial health and operational efficiency. This is a strong result compared to many biotech companies that are still in the development phase and not yet generating significant cash flow.
• The settlement of $495 million of convertible debt in cash is a positive move, reducing potential share dilution and demonstrating financial discipline. This is a better approach than issuing new convertible instruments, which can dilute shareholder value.
• BioMarin's long-term guidance of $4 billion in total revenue by 2027 and a 40% non-GAAP operating margin starting in 2026 is ambitious but achievable given their current growth trajectory. This is a strong target compared to many other biotech companies that are still in the early stages of commercialization.

Stakeholder Impact

• Shareholders will benefit from the increased profitability, strong revenue growth, and reduced share dilution.
• Employees may experience changes due to the organizational redesign efforts.
• Patients will benefit from the continued development and commercialization of innovative therapies.
• Customers will have access to a broader range of treatments as BioMarin expands its product portfolio.
• Suppliers and creditors will benefit from the company's strong financial position and cash flow.

Next Steps

• BioMarin will continue to advance its clinical programs, including the pivotal study for VOXZOGO in hypochondroplasia.
• The company plans to initiate the first-in-human study for BMN 333 in early 2025.
• BioMarin expects to receive initial proof-of-concept data for BMN 351 in 2025.
• The company will start dosing the multiple-ascending dose phase of the study for BMN 349 by the end of the year.
• BioMarin anticipates data from the phase 3 study with PALYNZIQ in adolescents in 2025.
• The company expects to submit an IND for BMN 390 and potentially BMN 370 in the second half of 2025.
• BioMarin will pursue VOXZOGO access into more than 20 additional countries by 2027.

Key Dates

Keywords

BioMarin, VOXZOGO, Enzyme Therapies, Revenue Growth, EPS, Financial Results, Biotechnology, Pharmaceutical, Clinical Trials, Rare Diseases